Our $18 million Series B financing was led by Samsara BioCapital, and included participation from new investor Bruker Corporation, a global leader in mass spectrometry. All of our existing major investors contributed to the round as well, including Genoa Ventures, ND Capital, Paladin Partners Investments, Trancos Ionpath Investors, Norwich Ventures, and Vertical Venture Partners Growth Fund. We thank all of them for their commitment to Ionpath!
These investors believe in our mission to revolutionize tissue imaging and deliver on the promise of precision medicine through our MIBI (multiplexed ion beam imaging) technology. In an announcement about the financing, Mike Dybbs, Partner at Samsara BioCapital and Ionpath board member, said: “Developed by pathologists for translational researchers, Ionpath’s MIBI™ platform delivers a revolutionary way to visualize phenotypic profiles, enabling rich, sensitive spatial analysis of tissue microenvironments.”
And Rohan Thakur, Executive Vice President, Bruker Corporation, added: “Bruker is honored to support Ionpath in the further development and commercialization of its MIBI technology, which is already helping researchers solve some of the most complex problems in solid tumor oncology. We believe the synergies between label-free MALDI imaging for endogenous metabolites, lipids, and glycans, coupled to MIBI multiplexed sub-cellular protein imaging, will accelerate adoption of mass spectrometry approaches for pathology.”
Our MIBI technology is accessible to scientists using our MIBIscope instrument or through our end-to-end Research Services offering. Start a pilot project with us and see how high-definition spatial proteomics can transform your research and development.